Navigation Links
SuperGen Reports 2008 Second Quarter Financial Results
Date:8/4/2008

ipent and SurfaceSafe representing the initial recognition of the deferred gain on sale of products to Mayne Pharma and also the recognition of gains on the sale of other products to Intas Pharmaceuticals.

Loss from operations for the six months ended June 30, 2008 was $4.2 million compared with income from operations of $6.4 million for the same prior year period. The Company reported a net loss for the six months ended June 30, 2008 of $5.9 million, or $0.10 per share, compared with net income of $7.7 million, or $0.14 per share, for the same prior year period. The net loss for the six months ended June 30, 2008 includes a non-operating charge of $3.1 million that reflects an other than temporary decline in value of the Company's equity investments. There was no similar non-operating charge in the same prior year period.

As of June 30, 2008, the Company had approximately $87.6 million in current and non-current unrestricted cash, cash equivalents and marketable securities.

2008 Revised Annual Financial Guidance

The Company has not changed significantly its annual financial guidance from the 2008 first quarter conference call. Selected elements of our revised annual financial guidance include the following:

-- Royalty revenue for 2008 remains unchanged and is forecasted in a range from $32 million to $35 million.

-- Research and development expenses remain unchanged for 2008 and are expected to total approximately $34 million to $36 million.

-- Selling, general and administrative expenses have been reduced slightly from the previous annual guidance and are expected to total approximately $13 million for 2008.

-- The Company is forecasting to record a non-cash charge in the amount of $5.2 million to acquired in-process research and development during 2008 representing a potential milestone payment to the former Montigen stockholders. This payment made in the form of equity is contingent on the filing of an Inve
'/>"/>

SOURCE SuperGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer
2. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
3. SuperGen to Announce 2007 Fourth Quarter and Fiscal Year-End Financial Results March 3, 2008
4. SuperGen Reports 2007 Fourth Quarter and Annual Financial Results
5. SuperGen to Announce 2008 First Quarter Financial Results April 28, 2008
6. SuperGen to Webcast 3rd Annual Analyst Day on April 29, 2008
7. SuperGen Reports 2008 First Quarter Financial Results
8. SuperGen to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 29, 2008
9. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
10. QMed, Inc. Reports July Medicare SNP Enrollments
11. Phlo Affiliate Reports Expanded Coverage to Oregon Border

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...24/PRNewswire-FirstCall/--Sigma-AldrichCorporation...renceonTuesday,December1stat1:45PMGMTinLondon,7:45...adcastovertheInternetavailableat http://inve s ...ebcast"icontoaccessthisfile. ,, AboutSigma-Al...echnologycompany.Itschemicalandbiochemicalproducts...
(Date:11/24/2009)...f.,Nov.24/PRNewswire-FirstCall/--NeurogesX,Inc.(Na...elopingandcommercializingnovelpainmanagementtherap...hiefExecutiveOfficer,isscheduledtopresentatthe21st...ember1-2,2009atTheNewYorkPalaceHotelinNewYork,NewY...ncialOfficer,willbeavailabletorespondtoquestionsdu...
(Date:11/24/2009)...cyendpointhasbeenmetforpatientswithadvanced-stage,...v.24/PRNewswire-FirstCall/-AEternaZentarisInc.(NAS...ceuticalcompanyfocusedonendocrinetherapyandoncolog...dywithitstargetedcytotoxicpeptideconjugate,AEZS-10...tendometrialcancer.Inapersonalizedhealthcareapproa...
(Date:11/24/2009)...alif.,Nov.24/PRNewswire-FirstCall/--GenomicHealth,...nomicHealth,sExecutiveChairman,willpresentatthe21s...tyonTuesday,December1,2009at10:00a.m.ET. ,, Toa...sentation,visittheInvestorRelationssectionofGenomi...om .Pleaseconnecttothewebsiteatleast15minutesprior...
Breaking Biology Technology:NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Genomic Health to Present at Piper Jaffray Health Care Conference 2
...h,announced that Sustenex(TM), its all-natural dai...e. Each Sustenex(TM) capsule contains at least 2,b...rietary, patented strain,of Bacillus coagulans des.... Sustenex(TM) with GanedenBC30 Probiotic is desig...elivering ten times more probiotic cells,than most...
...egic and operational leadership to support expans... opportunities, COLUMBIA, Md., A...ent of Brad L. Stewart as President of the Company...elops and manufactures research and in,vitro diagn... assay,cell-mediated immunity (CMI)., (Photo: ht...
...e,Chairman and CEO, Egenix, Inc., announced the ap...e company,s scientific advisory board. Dr.,Petryla...Columbia,University Medical Center where he is Dir...l Oncology. He is the co-author of numerous peer r... in the treatment of cancers of,prostate, kidney, ...
Other Biology Technology:Ganeden Biotech Takes Sustenex(TM) National with GanedenBC30 Probiotic 2Ganeden Biotech Takes Sustenex(TM) National with GanedenBC30 Probiotic 3Cylex Announces Brad L. Stewart as President of the Company 2
(Date:11/24/2009)...et science is opening new doors to understanding h...the hearing of a marine mammal or if they hear it...ed X-ray scanners that NASA uses to detect flaws i...is now allowing scientists to peek inside the gian...d three-dimensional replicas of a whale,s hearing ...
(Date:11/24/2009)... NEW YORK (November 24, 2009) -- The Wi...a report revealing that the last remaining populat...cantly due to the rising tide of poaching and habi... help inform Russian officials of what needs to be...d,s biggest cat. , The report was r...
(Date:11/23/2009)...INNATINew research presents strong evidence that t...both outdoor traffic-related pollution and indoor ...n one or the other exposure alone. , Environme...nati (UC) College of Medicine have shown that chil...d particles and indoor endotoxin during early life...
Breaking Biology News(10 mins):Rocket science leads to new whale discovery 2Report shows dramatic decline in Siberian tigers 2Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2Predictors of disease behavior change in Crohn 26 23146 3Bs disease 54046 1Estrogen dependent switch tempers killing activity of immune cells 9527 1Estrogen dependent switch tempers killing activity of immune cells 9527 2STAT3 gene regulates cancer stem cells in brain cancer 9525 1STAT3 gene regulates cancer stem cells in brain cancer 9525 2
...terdam, 2 December 2008 - Elsevier is delighted to...e the official publisher of the quarterly peer-rev... ( www.elsevier.com/locate/esd ) on behalf of the ...nable development involves meeting present human n...ons. Energy is central to providing many of these ...
... Arctic is undergoing rapid transformation due to ...s ERS and Envisat satellites have been providing s... These long term data sets in combination with ESA... newly adopted European Commission policy called ,...policy highlights new opportunities in the region ...
...PEL HILL How marine animals find their way back t...ross thousands of miles of open ocean has mystifie...iologists at the University of North Carolina at C... the secret. , At the beginning of their lives, s...of their home area and "imprint" on it, according ...
Other Biology News:New publishing partnership for Energy for Sustainable Development 2ESA satellites focusing on the Arctic 2No place like home: New theory for how salmon, sea turtles find their birthplace 2No place like home: New theory for how salmon, sea turtles find their birthplace 3
Toxoplasma IgG ELISA Kit, Single from Bio-Quant Inc.
Agarose, low melting/gelling temperature high MW separation (> 1000 bp) from GE Healthcare, formerly Amersham Biosciences
Rubella IgM ELISA Kit, Single from Bio-Quant Inc.
Chlamydia pneumonia IgA ELISA Kit, Single from Bio-Quant Inc.
Biology Products: